易明医药涨2.19%，成交额1701.92万元，主力资金净流入147.33万元

Group 1 - The core viewpoint of the news is that Yiming Pharmaceutical has shown significant stock performance, with a year-to-date increase of 91.39% and a recent trading volume indicating active market interest [1] - As of September 10, Yiming Pharmaceutical's stock price reached 19.64 CNY per share, with a total market capitalization of 3.745 billion CNY [1] - The company has experienced a net inflow of main funds amounting to 1.4733 million CNY, with large orders contributing to 15.94% of total buying [1] Group 2 - Yiming Pharmaceutical's main business involves the research, production, and sales of chemical drugs (93.32% of revenue) and traditional Chinese medicine (6.10% of revenue) [1] - The company has been listed on the stock market since December 9, 2016, and has appeared on the trading leaderboard six times this year, with the latest occurrence on August 22, where it recorded a net purchase of 18.41 million CNY [1] - As of August 29, the number of shareholders decreased by 1.87% to 20,800, while the average circulating shares per person increased by 1.91% to 8,381 shares [2] Group 3 - For the first half of 2025, Yiming Pharmaceutical reported a revenue of 311 million CNY, reflecting a year-on-year decrease of 11.52%, and a net profit attributable to shareholders of 37.56 million CNY, down 5.27% year-on-year [2] - Since its A-share listing, the company has distributed a total of 114 million CNY in dividends, with 43.40 million CNY distributed over the past three years [3]